Pricing & Access· July 7, 2026 · 17 min read
BMS Portfolio Dossier: The Eliquis Cliff, Opdivo Lifecycle, and Cobenfy Bet
By Ran Chen#Orange Book#Purple Book#Medicare Part D
Topic
Cardiovascular
Cardiometabolic and cardiovascular drug access, outcomes evidence, payer policy, and affordability dynamics.
Evidence· July 7, 2026 · 21 min read
Calcium Channel Blocker Adverse Events in FAERS: 619,000 Reports and Class-Wide Signals
Evidence· July 6, 2026 · 18 min read
Beta-Blocker Adverse Events: FAERS By the Numbers
Pipeline· July 2, 2026 · 17 min read
The Anti-Obesity Phase 3 Pipeline: Active Trials and Mechanisms
By Ran Chen#GLP-1#Weight Loss#Clinical Evidence
Evidence· July 1, 2026 · 17 min read
ACE Inhibitors and ARBs in FAERS: 46,000 Reports in 2025 and the Core Signals
Pricing & Access· June 24, 2026 · 25 min read
Eli Lilly Portfolio Dossier: Diabetes, Obesity, and Insulin Pricing
Generics· June 24, 2026 · 17 min read
Generic Entresto Market Entry: 95% Price Erosion and the Payer Formulary Transition
By Ran Chen#Generics#Generic Entry#Drug Pricing
Pricing & Access· May 31, 2026 · 12 min read
GLP-1 appeal evidence after cardiometabolic comorbidity denial
By Ran Chen#GLP-1#Prior Authorization#Specialty Drugs
Pipeline· May 31, 2026 · 10 min read
Olezarsen Tryngolza sNDA preview for severe hypertriglyceridemia
By Ran Chen#PDUFA Date#FDA Approval#Clinical Evidence
Approvals· May 28, 2026 · 7 min read
Baxfendy coverage guide: baxdrostat access for uncontrolled hypertension
By Ran Chen#Hypertension#Cardiovascular#FDA Approval